Grace Therapeutics, Inc. (GRCE)

Over the past six months, Grace Therapeutics, Inc. (GRCE) stock has been impacted by several events. The FDA set April 23, 2026, as the PDUFA target date for GTx-104's NDA review. The company announced its Q3 fiscal year 2026 financial results, reporting a net loss of $2.3 million and $18.7 million in cash. Grace Therapeutics secured approximately $4.0 million through warrant exercises. The company presented data at healthcare and investor conferences, including data from the Phase 3 STRIVE-ON safety trial for GTx-104. Grace Therapeutics was granted its sixth U.S. patent for GTx-104, extending patent protection until 2043. Short interest in GRCE grew by 300.8% in March 2026. GRCE showed positive stock price momentum over 3, 6, 9, and 12 months.

There is no information available regarding demand seasonality for Grace Therapeutics, Inc.'s products or services. Demand for specialized treatments is generally driven by disease incidence and diagnosis rather than seasonal factors.

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing pharmaceutical products for rare and orphan diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industries. The company's pipeline includes GTx-104, an intravenous infusion for aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, an oral mucosal spray of betamethasone for Ataxia-Telangiectasia (A-T); GTx-101, a topical bioadhesive film-forming polymer for postherpetic neuralgia (PHN), though its development has been deprioritized; and GTx-201. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.

Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey, United States, and is involved in the development and commercialization of pharmaceutical products in Canada. The company aims for successful development and commercialization of its lead candidate, GTx-104, in the United States and developed regions globally, including China and Europe.

Grace Therapeutics, Inc. is positioned as a biopharma company focused on addressing unmet medical needs for rare and orphan diseases, particularly in neurological conditions, which contributes to a positive reputation. Positive clinical trial results from the Phase 3 STRIVE-ON trial, the FDA submission and PDUFA date for GTx-104, the issuance of a new U.S. patent, and conference presentations have positively affected the company's reputation. The company faces inherent risks associated with drug development and has historically operated with no meaningful revenue and consistent cash burn.

Grace Therapeutics, Inc. (GRCE) has a diverse ownership structure, including institutional, individual, and retail investors. There were 23 institutional owners and shareholders holding 4,327,617 shares, with major holders including Nantahala Capital Management, LLC, AIGH Capital Management LLC, and Vanguard Group Inc. The largest individual shareholder is Grace 2018 Irrevocable Trust Rajitha, owning 4,689,547 shares, representing 30.31% of the company.